Sirukumab

Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis[1][2].

Product Specifications

CAS Number

[1194585-53-9]

Product Name Alternative

CNTO-136

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/sirukumab.html

Purity

96.83

Solubility

10 mM in DMSO

Smiles

[Sirukumab]

Molecular Weight

(144.58 kDa)

References & Citations

[1]Brad H Rovin, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis. Arthritis Rheumatol. 2016 Sep;68 (9) :2174-83.|[2]Bartoli F, et al. Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018[J]. Expert Review of Clinical Immunology, 2018, 14 (7) : 539-547.|[3]Gardner D, et al. THU0042 Preclinical Characterization of Sirukumab, a Human Monoclonal Antibody that Targets Human Interleukin-6 Signaling[J]. Annals of the Rheumatic Diseases, 2015, 74: 207.